Reported Earnings • May 19
First quarter 2026 earnings released: kr0.12 loss per share (vs kr0.081 loss in 1Q 2025) First quarter 2026 results: kr0.12 loss per share (further deteriorated from kr0.081 loss in 1Q 2025). Revenue: kr53.0k (down 100% from 1Q 2025). Net loss: kr12.9m (loss widened 129% from 1Q 2025). Revenue is forecast to grow 3.6% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to kr3.67, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 474% over the past three years. Valuation Update With 7 Day Price Move • Apr 15
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to kr3.87, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 19x in the Biotechs industry in Sweden. Total returns to shareholders of 465% over the past three years. New Risk • Apr 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr348.2m market cap, or US$37.6m). Duyuru • Apr 10
Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026 Sprint Bioscience AB (publ), Annual General Meeting, May 13, 2026, at 15:00 W. Europe Standard Time. Location: sprint biosciences premises at novum, halsovagen 7, 141 57 huddinge, Sweden Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to kr2.38, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 17x in the Biotechs industry in Sweden. Total returns to shareholders of 236% over the past three years. Duyuru • Mar 18
Sprint Bioscience AB (publ) Presents New Preclinical Data On Dcps Program At The Aacr Annual Meeting Sprint Bioscience AB (publ) announced that new preclinical data from the company’s DCPS program will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place on April 17, 2026, in San Diego, USA. The poster presentation summarizes new research findings supporting DCPS inhibition as a valid therapeutic strategy for patients with acute myeloid leukemia (AML). The results deepen the scientific understanding of DCPS biology and highlights its potential to improve patient stratification in AML. The poster “Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemia” will be presented by Madhurendra Singh, Associate Principal Scientist at Sprint Bioscience. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to kr2.14, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 29x in the Biotechs industry in Sweden. Total returns to shareholders of 269% over the past three years. New Risk • Jan 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr39m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr155.1m market cap, or US$16.8m). Recent Insider Transactions • Dec 02
Independent Chairman of the Board recently bought kr95k worth of stock On the 28th of November, Bjorn Sjostrand bought around 60k shares on-market at roughly kr1.59 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Bjorn's only on-market trade for the last 12 months. Reported Earnings • Nov 26
Third quarter 2025 earnings released: kr0.08 loss per share (vs kr0.075 loss in 3Q 2024) Third quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.075 loss in 3Q 2024). Revenue: kr5.27m (down 64% from 3Q 2024). Net loss: kr8.42m (loss widened 62% from 3Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 27
Second quarter 2025 earnings released: kr0.083 loss per share (vs kr0.083 loss in 2Q 2024) Second quarter 2025 results: kr0.083 loss per share (in line with 2Q 2024). Revenue: kr14.2m (down 15% from 2Q 2024). Net loss: kr7.37m (loss widened 28% from 2Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Price Target Changed • Jun 02
Price target decreased by 33% to kr2.00 Down from kr3.00, the current price target is provided by 1 analyst. New target price is 389% above last closing price of kr0.41. Stock is down 67% over the past year. The company posted a net loss per share of kr0.26 last year. Reported Earnings • May 28
First quarter 2025 earnings released: kr0.081 loss per share (vs kr0.044 loss in 1Q 2024) First quarter 2025 results: kr0.081 loss per share (further deteriorated from kr0.044 loss in 1Q 2024). Revenue: kr14.3m (down 20% from 1Q 2024). Net loss: kr5.64m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. New Risk • May 18
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (kr46.3m market cap, or US$4.73m). Duyuru • Apr 05
Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025 Sprint Bioscience AB (publ), Annual General Meeting, May 07, 2025, at 15:00 W. Europe Standard Time. Location: at sprint bioscience`s, premises, at novum Sweden Reported Earnings • Feb 16
Full year 2024 earnings released: kr0.26 loss per share (vs kr0.006 loss in FY 2023) Full year 2024 results: kr0.26 loss per share (further deteriorated from kr0.006 loss in FY 2023). Revenue: kr67.4m (up 31% from FY 2023). Net loss: kr18.3m (loss widened kr17.8m from FY 2023). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 15
Price target increased by 10% to kr3.20 Up from kr2.90, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.52. Stock is up 69% over the past year. Duyuru • Dec 18
Sprint Bioscience AB (Publ) Adds New Cancer Drug Program to Portfolio Sprint Bioscience AB (publ) announced that the company is broadening its portfolio with a drug development program for the treatment of acute myeloid leukemia (AML). The program targets the decapping scavenger enzyme (DCPS), a target protein that has been validated both in scientific literature and by Sprint Bioscience in collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet. The initiation of Sprint Bioscience's DCPS program is part of the company's strategy to capitalize on its platform for small-molecule drug discovery to broaden the portfolio in the cancer area and to bring more opportunities for future licensing deals. The DCPS program focuses on a target protein that degrades a metabolite resulting from the processing of mRNA. Both small-molecule inhibition and genetic knock-down of DCPS affects the differentiation and proliferation of several AML cell lines as well as patient-derived samples. Furthermore, healthy tissue seems to be insensitive to DCPS inhibition, indicating that DCPS inhibitors could offer a safe and effective treatment option for AML patients. Sprint Bioscience has also identified biomarkers to predict response to DCPS inhibition, enabling patient selection and clinical success for patients with unmet therapeutic needs. AML is a severe type of blood cancer. The Global Burden of Disease study estimates that about 140,000 people around the world are diagnosed with AML on a yearly basis. There is an urgent medical need to identify safe and effective therapies to improve treatment outcomes. Sprint Bioscience's portfolio now consists of six internal drug development programs (five of which are in cancer) and one program that has been licensed to Day One Biopharmaceuticals. New Risk • Dec 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (kr121.5m market cap, or US$11.0m). New Risk • Nov 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr103.1m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (kr103.1m market cap, or US$9.38m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Nov 01
Third quarter 2024 earnings released: kr0.075 loss per share (vs kr0.41 profit in 3Q 2023) Third quarter 2024 results: kr0.075 loss per share (down from kr0.41 profit in 3Q 2023). Revenue: kr14.8m (down 63% from 3Q 2023). Net loss: kr5.21m (down 118% from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to kr1.78, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 48x in the Biotechs industry in Sweden. Total loss to shareholders of 64% over the past three years. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to kr1.20, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 43x in the Biotechs industry in Sweden. Total loss to shareholders of 80% over the past three years. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to kr1.52, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past three years. Reported Earnings • Feb 16
Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022) Full year 2023 results: kr0.006 loss per share (improved from kr1.43 loss in FY 2022). Revenue: kr54.3m (up kr54.2m from FY 2022). Net loss: kr438.0k (loss narrowed 99% from FY 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022) Third quarter 2023 results: EPS: kr0.41 (up from kr0.33 loss in 3Q 2022). Revenue: kr41.2m (up kr41.2m from 3Q 2022). Net income: kr28.6m (up kr41.9m from 3Q 2022). Profit margin: 70% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 28
Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022) Second quarter 2023 results: kr0.17 loss per share (improved from kr0.45 loss in 2Q 2022). Net loss: kr11.7m (loss narrowed 35% from 2Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Buying Opportunity • May 30
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 3.4%. The fair value is estimated to be kr0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Earnings per share has grown by 35%. Buying Opportunity • Mar 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.9%. The fair value is estimated to be kr0.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 22% over the last 3 years. Earnings per share has grown by 31%. Reported Earnings • Feb 17
Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021) Full year 2022 results: kr1.43 loss per share (further deteriorated from kr0.85 loss in FY 2021). Net loss: kr60.2m (loss widened 140% from FY 2021). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to kr3.30 Down from kr16.05, the current price target is provided by 1 analyst. New target price is 360% above last closing price of kr0.72. Stock is down 86% over the past year. The company posted a net loss per share of kr0.85 last year. Reported Earnings • Oct 30
Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021) Third quarter 2022 results: kr0.33 loss per share (down from kr0.54 profit in 3Q 2021). Net loss: kr13.3m (down 176% from profit in 3Q 2021). Revenue is forecast to grow 79% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021) Second quarter 2022 results: kr0.45 loss per share. Revenue: kr24.0k (up 100% from 2Q 2021). Net loss: kr17.9m (loss widened 29% from 2Q 2021). Reported Earnings • May 13
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: kr0.36 loss per share. Revenue: kr53.0k (down 87% from 1Q 2021). Net loss: kr14.2m (loss widened 3.7% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Breakeven Date Change • Apr 27
Forecast to breakeven in 2023 The analyst covering Sprint Bioscience expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2023. Average annual earnings growth of 79% is required to achieve expected profit on schedule. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Director Rune Nordlander is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 18
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.0m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 5.8% compared to a 216% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 17
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: kr0.85 loss per share (up from kr2.55 loss in FY 2020). Revenue: kr35.1m (up 83% from FY 2020). Net loss: kr25.1m (loss narrowed 41% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.3%. Over the next year, revenue is expected to shrink by 5.9% compared to a 213% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr33.9m (up 399% from 3Q 2020). Net income: kr17.6m (up kr23.6m from 3Q 2020). Profit margin: 52% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 15
Director recently bought kr336k worth of stock On the 10th of September, Rune Nordlander bought around 68k shares on-market at roughly kr4.95 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Aug 18
Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr12.0k (down 100% from 2Q 2020). Net loss: kr13.9m (loss widened 11% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Reported Earnings • May 14
First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: kr408.0k (down 93% from 1Q 2020). Net loss: kr13.7m (loss widened 40% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Executive Departure • Mar 03
Interim Chief Executive Officer Charlotte Leife has left the company On the 1st of March, Charlotte Leife's tenure as Interim Chief Executive Officer of the company ended after less than a year in the role. We don't have any record of a personal shareholding under Charlotte's name. Charlotte is the only executive to leave the company over the last 12 months. Under Charlotte's leadership, the company delivered a total shareholder return of -0.9%. Analyst Estimate Surprise Post Earnings • Feb 20
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 39%. Over the next year, revenue is forecast to grow 62%, compared to a 126% growth forecast for the Biotechs industry in Sweden. Is New 90 Day High Low • Feb 18
New 90-day low: kr6.52 The company is down 18% from its price of kr8.00 on 20 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. Reported Earnings • Feb 18
Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr19.6m (down 42% from FY 2019). Net loss: kr42.8m (loss widened 99% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 02
New 90-day low: kr7.10 The company is down 7.0% from its price of kr7.60 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. Reported Earnings • Nov 02
Third quarter 2020 earnings released: kr0.36 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr6.79m (up 55% from 3Q 2019). Net loss: kr5.99m (loss narrowed 17% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 32% per year.